Cancer, of all types, is one of the primary causes of death for all dogs in the United States. The incidence of cancer in dogs and cats approaches that of humans.
With a population of 83 million dogs and 95 million cats in the United States, cancer accounts for an ever larger number of veterinary cases. Previously, aside from euthanasia, pet owners had little recourse for the treatment of their cancer-stricken companions. However, advances in human medicine, and the subsequent adaptation of human therapeutics for use in veterinary medicine, have increased the options available to pet owners. This is evidenced by the fact that in 1991, the American College of Veterinary Internal Medicine approved veterinary oncology as aboard-certified discipline and, in 1994, recognized radiation oncology as an oncology specialty.

Currently, the veterinary cancer treatments that have been adapted from human medicine are surgery, radiation therapy, and chemotherapy.

Antibody therapeutics demonstrated to be highly successful and of low toxicity in human patients, however, have not been successfully adapted for use in veterinary medicine. The reason for this is the species specificity of these biologics which make the human drug inactive in pets.

The potential immune rejection of the human antibody therapeutic by the dog or cat immune system further complicates the direct translation of the human antibody therapeutics for veterinary use. Thus, there is an unmet veterinary medical need for dog and cat antibodies targeting dog and cat cancers. CanFel Therapeutics is committed to addressing this unmet need.